FLEETCOR Technologies, Inc.

Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual Meeting

Volatus Aerospace Marks Official Opening of Mirabel Facility as Canadian Manufacturing Operations Scale

Volatus Aerospace Releases Q2 2026 Financial Results

Volatus and Kraus Hamdani Aerospace Partner to Establish Sovereign Canadian Persistent Intelligence Capability

Volatus Aerospace to Showcase Advanced Aerospace, Autonomy and Intelligence Solutions at Farnborough International Airshow

Volatus Aerospace Opens 53,000-Square-Foot Mirabel Facility, Establishing Domestic Manufacturing Base for Autonomous Defence Systems

Volatus Aerospace Closes $34.5M Bought Deal Public Offering

Volatus Aerospace Partners with UCan Brave Tech to Advance Sovereign Canada–Ukraine Defence Technologies

Volatus Aerospace Inc. Announces $30 Million Bought Deal Public Offering of Common Shares

Volatus Aerospace Introduces Canadian Sovereign AI Flight Controller and Autonomy Stack at CANSEC 2026

Volatus Aerospace Selected to Advance to Next Phase of U.S. Drone Dominance Program

Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia

Fleetcor Technologies Q1 Earnings Call Highlights

Volatus Aerospace Inc. (FLT:CA) Q1 2026 Earnings Call Transcript

Volatus Aerospace Reports First Quarter 2026 Financial Results, Records Highest Q1 Gross Margins in Company's History

Volatus Aerospace to Release First Quarter 2026 Financial Results and Host Earnings Call on May 14, 2026

Fleetcor Technologies Q4 Earnings Call Highlights

Volatus Aerospace Inc. (FLT:CA) Q4 2025 Earnings Call Transcript

Volatus Aerospace Inc. (FLT) Opens the Market

Volatus Aerospace Announces Graduation to Toronto Stock Exchange; Trading to Commence March 20, 2026